{"changeSha256":"816637e1bf3738c2ea3fe6bc37a464ad4632bcf0b5c6871e956119a93fa2952f","changedAt":"2026-07-27","changedFields":[{"after":"An amylin and GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.","before":"An amylin and GLP-1 receptor agonist candidate represented in ClinicalTrials.gov.","field":"Profile summary"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/amycretin/versions/2/","version":2},"id":"profile:amycretin:v2","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.","peptideSlugs":["amycretin"],"previousChangeEvent":null,"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/amycretin/versions/1/","version":1},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"ctg-nct06049329-v6","name":"ClinicalTrials.gov","sourceClass":"A","title":"Oral Amycretin in Japanese Men With Obesity · record history version 6 · last update posted 2025-03-05","url":"https://clinicaltrials.gov/study/NCT06049329?a=6&tab=history","verifiedAt":"2026-07-22"}],"subject":{"slug":"amycretin","type":"profile"}}